The firm is a venture capital fund and company builder with headquarters in Germany and an additional office in the US and is allocating their funds primarily into companies in Europe and North America. There is an approximately 50:50 split between traditional equity investments and venture creation, the initial investment size is in the range from $1-5M in the Seed Round and additional $10-15 for subsequent rounds.

The firm invests in technologies that can treat age-related disease and damages associated with aging, such as altered protein homeostasis, cellular senescence, stem cell exhaustion, etc. The firm is primarily focused on therapeutics, but is also considering advanced therapy medicinal products (gene therapy, cell therapy, tissue engineering) as long as they are relevant to the firm’s mission in targeting the basic mechanisms contributing to age-related disease. However, medical devices are currently not an area of focus. In therapeutics, the firm looks mostly at pre-clinical technologies with a validated proof-of-concept. The firm will consider companies in their later stages but prefers working with early-stage companies to provide company building and strategic support.

The firm can work with all types of management teams. The firm places higher importance in the actual science or technology in development as well as solid IP position. The firm seeks to work closely with their portfolio companies and can assist with building and structuring a full management team. As the firm generally comes in as the first institutional investor, they prefer to lead rounds and take a board seat, but are also open to joining strong syndicates.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

The venture fund is a healthcare investment firm founded in 1992 with offices in Massachusetts and California. The company actively finds and invests in life sciences companies (both public and private) that seek to cure major diseases by translating scientific innovations into positive clinical outcomes. With $1.5 billion in assets under management, the firm typically makes investments ranging from $3 to $25 million depending on the target company’s stage of development and capital requirements. The firm considers investments into companies located anywhere around the globe.

The firm invests in breakthrough therapeutics, with a focus on oncology. However, the firm also considers investments into companies developing platform technologies. While the firm considers

investment from seed stage to private investment in public equity, the firm’s ideal company has an asset that is pre-clinical or in early clinical trials.

The firm invests primarily in private companies but will also consider private investment in public equity opportunities.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

The firm is a multinational biopharmaceutical corporation. The firm develops and produces medicines, vaccines and consumer health care products. The firm looks to invest in/partner with academic research and start-up companies for developing innovative therapies and delivering value to the company. The firm has established a number of partnering models including Academic & Start-Up Company Partnerships, Alternative Development / Funding Models, Centers for Therapeutic Innovation, Global Scouting, Open Innovation Portal and a Corporate Venture Fund. The firm also takes part in equity rounds, usually with rights attached. The company is open to make co-development deals to help early-stage biotech companies, and is currently looking for new investment opportunities across the globe with a focus in North America, Europe, and Asia.c

The firm is currently looking for innovative therapeutics and medical technologies targeting the following areas: Cardiovascular & Metabolic Diseases, Immunology & Inflammation, Neuroscience, Oncology (including Immuno-Oncology), Rare Diseases (Gene Therapy as a platform), and Vaccines. In neuroscience, the firm is focused on neurodegenerative diseases, particularly technology in Alzheimer’s and Parkinson’s disease, and is open to preclinical (conception) to Ph III technology in this strategy. Neuroscience companies in neuroinflammation (i.e. microglia) and other emerging CNS areas, including CNS rare diseases and symptom-treating technology, require robust Ph II (or beyond) data. For rare indications, the firm requires a therapeutic approach that directly addresses the genetic cause of the disease. The firm is also open to other life science technologies that may speed up the development process, including lab technology and drug development enabling technologies. The firm also seeks in-licensing products for development. Overall, the firm is open to all stages of development, as the firm has separate teams to encompass all phases of development from preclinical to commercial stages.

The firm collaborates – in multiple formats – with both privately held and public life science companies with experienced management teams, innovative technologies, and an established scientific unit.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

The corporate venture arm of a big pharma is a diversified business based in Tokyo focused on three primary sectors: Materials, Homes and Healthcare. The team is based in offices outside Boston, MA and Menlo Park, CA. The fund has an evergreen structure looking to allocate between $1-$3 million per deal initially and up to $5 million over the life of the investment. The firm is seeking to invest in approximately 2-4 companies over the next 12 months and is open to investing in companies across the globe.

Sectors of interest include: pharmaceuticals, medical devices and digital health. Therapeutic and product areas of interest include: Pain, critical care, musculoskeletal disease, kidney disease, DDS, patient monitoring technologies, bioprocessing technologies, digital therapeutics. The firm is open to all stages of investment, with a general preference toward companies with at least some early clinical data.

The firm invests in private companies and is willing to work with all types of management teams including incomplete teams. The firm generally requests at least an observer seat following investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.